How ketamine is rewiring the brain to fight severe depression
A once-controversial drug is now transforming depression treatment. Ketamine, originally an anaesthetic from the 1960s, has emerged as a fast-acting therapy for severe depression. Its refined form, esketamine, gained FDA approval in 2019 and reached German clinics by late 2023, offering hope where traditional treatments fail.
Ketamine was first created in 1962 and approved as a surgical anaesthetic in 1970. Decades later, researchers discovered its unexpected potential for mental health. Unlike standard antidepressants that target serotonin, ketamine works on glutamate—the brain's most widespread chemical messenger.
Early claims about ketamine's rapid effects were met with doubt. But repeated studies confirmed its ability to ease symptoms in as little as one to four hours. Traditional antidepressants, by contrast, often take up to six weeks to work. The drug also reduces suicidal thoughts quickly, making it a critical option for high-risk patients.
Ketamine's impact goes beyond short-term relief. It triggers synaptogenesis—the rapid regrowth of neural connections damaged by chronic stress. Esketamine, its purified version, helps the brain form new pathways, leading to lasting improvements even after the drug leaves the body. Clinical use now pairs it with other antidepressants and therapy for treatment-resistant cases.
Success rates are striking: up to 70% of patients who failed at least two traditional treatments respond to ketamine. However, its use remains tightly controlled. Doctors administer it in supervised settings to monitor temporary effects on blood pressure and heart rate.
Beyond depression, ketamine shows promise for other brain-related conditions. Studies explore its use in PTSD, bipolar disorder, Parkinson's-related depression, and chronic stress.
Esketamine became available in Germany in late 2023, expanding access to this fast-acting treatment. While its global adoption varies, the drug's ability to rewire damaged neural pathways offers a lifeline for those with severe, treatment-resistant depression. Further research may unlock even broader applications for brain health.
